Role of the mTOR pathway in normal and tumoral adrenal cells

Neuroendocrinology

Volumn 92, Issue SUPPL. 1, 2010, Pages 28-34

  De Martino, M C ^a,b   Van Koetsveld, P M ^a   Pivonello, R ^b   Hofland, L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Adrenocortical carcinoma; Everolimus; Insulin like growth factor; mTOR; mTOR inhibitor; Pheochromocytomas; Rapamycin; Temsirolimus

Indexed keywords

DEFOROLIMUS; EVEROLIMUS; GLUCAGON LIKE PEPTIDE 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN; SOMATOMEDIN B; TEMSIROLIMUS; VASCULOTROPIN;

ADRENAL CORTEX CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 77956533046     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314280     Document Type: Conference Paper

References (37)

1. Latronico AC, Chrousos GP: Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab 1997; 82: 1317-1324.
2. Kirschner LS: Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 2006; 91:14-21.
3. Pacak K, Eisenhofer G, Ahlman H, Born-stein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS: Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 20 05. Nat Clin Pract 20 07; 3: 92-102.
4. Lenders JW, Eisenhofer G, Mannelli M, Pa-cak K: Phaeochromocytoma. Lancet 2005; 366:665-675.
5. Fassnacht M, Allolio B: Clinical management of adrenocort ica l carcinoma. Best Prac Res 2009; 23: 273-2 8 9.
6. Allolio B, Fassnacht M: Clinical review: ad-renocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006; 91:2027-2037.
7. Fassnacht M, Kreissl MC, Weismann D, Al-lolio B: New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 2009; 123:117-141.
8. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M: Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol 2008; 61:787-793.
9. Fottner C, Minnemann T, Kalmbach S, Weber MM: Overexpression of the insulin-like growth factor I receptor in human pheo-chromocytomas. J Mol Endocrinol 2006; 36: 279-287.
10. Takekoshi K, Isobe K, Yashiro T, Hara H, Ishii K, Kawakami Y, Nakai T, Okuda Y: Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci 2004; 74: 863-871.
11. Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J: VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. Apmis 2003; 111:458-464.
12. Hanna SC, Heathcote SA, Kim WY: mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther 2008; 8:283-292.
13. Wan X, Helman LJ: The biology behind mTOR inhibition in sarcoma. Oncologist 2007; 12:1007-1018.
14. Konings IR, Verweij J, Wiemer EA, Sleijfer S: The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets 2009; 9: 439-450.
15. Le Tourneau C, Faivre S, Serova M, Raymond E: mTORC1 inhibitors: is temsiroli-mus in renal cancer telling us how they re-a lly work? Br J Cancer 20 08; 99: 11 9 7-1 2 0 3.
16. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
17. Liu P, Cheng H, Roberts TM, Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev 2009; 8: 627-644.
18. Fottner C, Hoeflich A, Wolf E, Weber MM: Role of t he i nsulin-l ike g row t h factor system in adrenocortical growth control and carci-nogenesis. Horm Metab Res 2004; 36: 397-405.
19. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50.
20. Fassnacht M, Weisman n D, Eber t S, Adam P, Zink M, Beuschlein F, Hahner S, Allolio B: AKT is highly phosphorylated in pheochro-mocytomas but not in benign adrenocortical tumors. J Clin Endocrinol Metab 2005; 90: 4366-4370.
21. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB: Novel and evolving therapies in the treatment of malignant phaeo-chromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Met-abol Res 2009; 41:697-702.
22. Powers JF, Tischler AS, Cherington V: Discordant effects of rapamycin on proliferation and p70S6 kinase phosphorylation in normal and neoplastic rat chromaffin cells. Neuro-sci Lett 1999; 259: 137-14 0.
23. Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, Kagedal B, Eksborg S, Sveinbjornsson B, Kogner P: Inhibitors of mammalian target of rapamycin downregu-late MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008; 27:2910-2922.
24. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H: Inhibition of the PI3K pathway suppresses hormonal secretion and limits growth in pheochromocytoma cells. Wld J Surg 2009; 33:2452-2457.
25. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD: Preclinical target i ng of t he t y pe I insu li n-li ke g row t h fac tor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009; 94: 204-212.
26. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-El-lenson L, Parsons R: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 ki-nase activity in Pten+/-mice. Proc Natl Acad Sci USA 2001; 98:10320-10325.
27. Van Nederveen FH, Perren A, Dannenberg H, Petri BJ, Dinjens WN, Komminoth P, De Krijger RR: PTEN gene loss, but not mutation, in benign and malignant phaeochro-mocytomas. J Pathol 2006; 209:274-280.
28. Puc J, Placha G, Wocial B, Podsypanina K, Parsons R, Gaciong Z: A na lysis of P T EN mutation in non-familial pheochromocytoma. Ann NY Acad Sci 2006; 1073:317-331.
29. Cantini G, Lombardi A, Piscitelli E, Poli G, Ceni E, Marchiani S, Ercolino T, Galli A, Se-rio M, Mannelli M, Luconi M: Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracel-lular signaling. PPAR Res 2008; 2008:904041.
30. Lu X, Kambe F, Cao X, Yamauchi M, Seo H: Insulin-like growth factor-I activation of Akt survival cascade in neuronal cells requires the presence of its cognate receptor in caveolae. Exp Cell Res 2008; 314: 342-351.
31. Kleijn M, Korthout MM, Voorma HO, Thomas AA: Phosphorylation of the eIF4E-binding protein PHAS-I after exposure of PC12 cells to EGF and NGF. FEBS Letters 1996; 396: 16 5-17 1.
32. Harthill JE, Pozuelo Rubio M, Milne FC, MacKintosh C: Regulation of the 14-3-3-binding protein p39 by growth factors and nutrients in rat PC12 pheochromocytoma cells. Biochem J 2002; 368: 565-572.
33. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, Ma-ciel CC, Mattos GE, Jorge AA, Mendonca BB, Latronico AC: Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin En-docrinol Metabol 20 08; 93: 3524-3531.
34. M is aw a A, Hosoi H, Tsu c h iy a K, Su g i mot o T: Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer 20 03; 10 4: 233-237.
35. Kimura R, Okouchi M, Fujioka H, Ichi-yanagi A, Ryuge F, Mizuno T, Imaeda K, Okaya ma N, Ka m iy a Y, Asa i K, Joh T: Gluca-gon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 2009; 162: 1212-1219.
36. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wieden-mann B: Daily oral everol imus activity i n patients with metastatic pancreatic neuroen-docrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28:69-76.
37. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Ber nstam F: Eff ic ac y of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuro-endocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318.